Clinical Trial

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females 18-26 Years of Age.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-26; most recent amendment 2025-07-28.
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-11-02
Trial Details
NCT Number NCT06197802
Lead Sponsor Xiamen University
Collaborators: Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Conditions Cervical Cancer, Condylomata Acuminata
Enrollment 392 participants
Start Date 2023-12-30
Primary Completion 2024-04-05 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-31